Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antisense IAP oligonucleotides and uses thereof

a technology of oligonucleotides and antisense, which is applied in the field of antisense iap oligonucleotides, can solve problems such as poor prognosis, and achieve the effect of facilitating production

Inactive Publication Date: 2007-05-31
AEGERA THERAPEUTICS INC +1
View PDF16 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

"The patent text describes the discovery of a protein called IAP (inhibitor of apoptosis) that is overexpressed in various cancer types and is associated with poor prognosis and resistance to chemotherapy. The patent describes a method of inhibiting IAP using an antisense oligonucleotide that can decrease the expression of IAP and induce apoptosis (cell death) in cancer cells. The patent also describes a negative regulator of IAP called a zinc finger nucleic acid that can enhance the inhibition of IAP. The technical effect of the patent is the development of new methods for treating cancer and other proliferative diseases by targeting the inhibitor of apoptosis pathway."

Problems solved by technology

In addition, we have found that nuclear localization, fragmentation of the IAPs, and overexpression of the IAPs in the presence of p53 mutations correlate with a cancer diagnosis, a poor prognosis, and resistance to numerous chemotherapeutic cancer drugs.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antisense IAP oligonucleotides and uses thereof
  • Antisense IAP oligonucleotides and uses thereof
  • Antisense IAP oligonucleotides and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Testing of Antisense Oligonucleotides

[0095] 1. Complete panel of adenovirus constructs. The panel may consist of approximately four types of recombinant virus. A) Sense orientation viruses for each of the IAP open reading frames. These viruses are designed to massively overexpress the recombinant protein in infected cells. XIAP, HIAP1, HIAP2, and NAIP. B) Antisense orientation viruses in which the viral promoter drives the synthesis of an MRNA of opposite polarity to the iap mRNA, thereby shutting off host cell synthesis of the targeted protein coding region. XIAP, HIAP1, HIAP2, and NAIP “antisense” constructs are used for production of such antisense IAPs. C) Sub-domain expression viruses. These constructs express only a partial IAP protein in infected cells. We have data indicating that deletion of the zinc finger of XIAP renders the protein more potent in protecting cell against apoptotic triggers. This data also indicates that expression of the zinc finger alone will indicate a...

example 2

Antisense Oligonucleotide (ODN) Selection

[0103] We selected 96 and 98, mostly non-overlapping, 19-mer antisense oligonucleotide (ODN) sequences for XIAP and HIAP1, respectively, based on the selection criteria listed below. In the case of XIAP, we selected 96 sequences (each being 19 nucleobases in length) (SEQ ID NOS: 1 through 96; Table 1) from a region approximately 1 kb upstream of the start codon to approximately 1 kb downstream of the stop codon of the cDNA sequence (FIG. 15). This blanketed approximately 50% of the coding region, and immediate 5′ and 3′ UTR sequences (i.e., 96 19-mers span 1.8 kb of sequence, while the targeted region is approximately 3.5 kb in length, comprised of a coding region of 1.5 kb plus 1 kb either side of UTR sequences).

TABLE 1XIAP Antisense OligonucleotidesPositionAntisensein XIAPOligonucleotideSEQ ID NO:CodeSequenceSequence1A12AAAATTCTAAGTACCTGCA2B121TCTAGAGGGTGGCTCAGGA3C144CAGATATATATGTAACACT4D178TGAGAGCCCTTTTTTTGTT5E1110AGTATGAAATATTTCTGAT6F1...

example 3

Antisense Oligonucleotide Synthesis

[0108] The antisense oligonucleotides were synthesized by IDT (Integrated DNA Technologies, USA) as chimeric, second-generation oligonucleotides, consisting of a core of phosphodiester DNA residues flanked on either side by two 2′-O methyl RNA residues with a phosphorothioate linkage between the flanking RNA residues. The oligonucleotides were provided in a 96-well plate, as well as matching tubes, with a minimum of 12 ODs of oligo DNA, which provided ample material for transfections (greater than a hundred assays ih the 96-well format) when the detection method is a sensitive method, such as TaqMan quantitative PCR, or an ELISA. Once the positive hits were identified (see below), the antisense oligonucleotides were re-synthesized with 3, instead of 2, flanking RNA residues to further increase stability / nuclease resistance. In addition, for validation purposes, appropriate controls (such as scrambled, 4-base mismatch, and reverse polarity oligonuc...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
optimal time pointsaaaaaaaaaa
TaqMan real time PCRaaaaaaaaaa
Login to View More

Abstract

The present invention features antisense IAP oligonucleotides and other negative regulators of the IAP anti-apoptotic pathway, and methods for using them to enhance apoptosis.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. Ser. No. 09 / 672,717 (now allowed), filed Sep. 28, 2000.FIELD OF THE INVENTION [0002] The invention relates to antisense IAP oligonucleotides and methods of using them to increase apoptosis. BACKGROUND OF THE INVENTION [0003] One way by which cells die is referred to as apoptosis, or programmed cell death. Apoptosis often occurs as a normal part of the development and maintenance of healthy tissues. The process may occur so rapidly that it is difficult to detect. [0004] The apoptosis pathway is now known to play a critical role in embryonic development, viral pathogenesis, cancer, autoimmune disorders, and neurodegenerative diseases, as well as other events. The failure of an apoptotic response has been implicated in the development of cancer, autoimmune disorders, such as lupus erythematosis and multiple sclerosis, and in viral infections, including those associated with herpes virus, poxvirus,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K48/00C07H21/02A61K38/00C12N15/113
CPCA61K38/00C12N15/113C12N2310/12C12N2310/315C12N2310/321C12N2310/341C12N2310/346C12N2310/3521
Inventor KORNELUK, ROBERT G.LACASSE, ERICBAIRD, STEPHENHOLCIK, MARTINYOUNG, SEAN
Owner AEGERA THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com